Summary of Clinical Use

Tadekinig alfa has advanced to Phase 3 clinical evaluation in patients with spontaneous activating mutations of the NLRC4 and with recurrent MAS-like flares driven by constitutive IL-18 hypersecretion. A further trial is evaluating tadekinig alfa in hemophagocytic lymphohistiocytosis patients with XIAP deficiency, which is a MAS-like syndrome that is characterised by high levels of serum IL-18. Favourable Phase 2 efficacy and safety of tadekinig alfa in patients with adult-onset Still's disease was reported in June 2018 [1].

Mechanism Of Action and Pharmacodynamic Effects

Tadekinig alfa binds circulating IL-18 and blunts IL-18-mediated pro-inflammatory responses [1].